Profile
Develops AI-driven software to improve the management of neurological disorders.
EnlitenAI, founded by Dr. Himanshu Misra in Tracy, California, emerged from personal tragedy—the loss of his son to drug-resistant epilepsy. The company focuses on developing AI-driven solutions for neurological and neurobehavioral disorders, with an initial emphasis on epilepsy and seizure management.
EnlitenAI’s flagship product, Neuroliten, is a cloud-based SaaS platform designed to aggregate and analyze multimodal data from wearables and IoT devices, enabling personalized treatment plans. Registered with the FDA as a Class I Software as a Medical Device (SaMD) in January 2026, Neuroliten supports clinicians by providing actionable insights without replacing their judgment. The company has partnered with UCHealth and received recognition at the Digital Health Awards.
EnlitenAI’s vision extends beyond epilepsy, aiming to address conditions like autism, Parkinson’s, and Alzheimer’s. The team includes seasoned professionals in digital health, data science, and clinical development, positioning EnlitenAI as a contender in the precision care space.
Who buys this
- Neurologists
- Caregivers of epilepsy patients
- Insurance carriers
- Healthcare providers
- Patients with neurological conditions
Publicly disclosed clients
- UCHealth
Strengths and what to watch
Strengths
- FDA-registered Class I SaMD status for Neuroliten
- Integration with FDA-cleared wearables and IoT devices
- Strong partnerships with healthcare providers like UCHealth
Watch for
- Dependence on wearable device adoption by patients
- Regulatory hurdles in expanding to other neurological conditions
- Competition from established healthcare tech companies
Recent moves
Key Information
- Founded
- 2020
- Headquarters
- Tracy, California
Frequently Asked Questions
What is EnlitenAI and what do they do?
EnlitenAI develops AI-powered software to improve neurological disorder management. Founded by Dr. Himanshu Misra after losing his son to epilepsy, the company focuses on conditions like epilepsy, with plans to expand to Parkinson's and Alzheimer's. Their flagship product Neuroliten analyzes wearable data for personalized treatment insights.
How does EnlitenAI's Neuroliten platform work?
Neuroliten is a cloud-based SaaS platform that aggregates and analyzes data from wearables and IoT devices. It processes multimodal neurological data to help clinicians create personalized treatment plans for epilepsy patients, without replacing medical judgment. The system provides actionable insights while maintaining FDA Class I SaMD compliance.
Is EnlitenAI's technology FDA approved?
Neuroliten is registered with the FDA as a Class I Software as a Medical Device (SaMD) since January 2026. This classification means it meets regulatory requirements for safety and effectiveness in supporting epilepsy management, though it integrates with other FDA-cleared wearables rather than replacing them.
Which hospitals use EnlitenAI's technology?
UCHealth is EnlitenAI's most notable partner, having announced their collaboration in August 2025. The partnership demonstrates clinical validation of Neuroliten's approach to epilepsy management through wearable data analysis. EnlitenAI continues expanding its healthcare provider network for broader adoption.
Can EnlitenAI help with conditions beyond epilepsy?
While initially focused on epilepsy, EnlitenAI plans to expand its AI platform to address other neurological conditions like autism, Parkinson's, and Alzheimer's. The company's technology framework for multimodal data analysis could potentially adapt to various neurobehavioral disorders with further development and regulatory approvals.
What devices work with EnlitenAI's Neuroliten system?
Neuroliten integrates with FDA-cleared wearables and IoT devices that collect neurological data. The platform aggregates this multimodal information into a unified dashboard for clinicians. Specific compatible devices aren't listed publicly, but the system is designed to work with medical-grade monitoring technologies.
Sources
- enlitenai.com — Neuroliten’s functionality and FDA registration
- enlitenai.com — Recent news and partnerships
- enlitenai.com — Founder and leadership details
- enlitenai.com — UCHealth partnership